Advice

On 16 March, 2015, the Medicines and Healthcare Products Regulatory Agency (MHRA) published a statement advising that, due to a change in the mode of administration, Takeda has made the decision to withdraw the marketing authorisation in the EU for ferumoxytol (Riensol), for the intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease.

Please see link to MHRA statement

Medicine details

Medicine name:
ferumoxytol (Rienso)
SMC ID:
833/13
Indication:
For the intravenous treatment of iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD).
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Status
Withdrawn
Date advice published:
11 February 2013